Advertisement
BBIO vs PMN
Which Stock Would AI Choose? BridgeBio Pharma (BBIO) vs. ProMIS Neurosciences (PMN) Stock Comparison
Key Takeaways
- BridgeBio Pharma (BBIO) boasts a larger market capitalization of approximately $14 billion and approved therapies for genetic diseases, contrasting with ProMIS Neurosciences' (PMN) $100 million market cap and early-stage neurodegenerative focus.
- BBIO has delivered over 100% one-year returns with recent Phase 3 trial successes bolstering momentum, while PMN shows year-to-date gains of around 60% amid clinical trial progress.
- Both stocks operate in high-growth biotech sectors, but BBIO's diversified pipeline and commercial products provide greater stability compared to PMN's higher volatility.
- Recent financing for PMN extends its runway, yet BBIO benefits from stronger analyst sentiment and broader market positioning.
- Investor interest in biotech innovation makes this BBIO vs. PMN stock comparison relevant for those eyeing relative performance in genetic and neurological therapies.
Introduction
This stock comparison pits BridgeBio Pharma (BBIO), a leader in genetic disease treatments, against ProMIS Neurosciences (PMN), an innovator in neurodegenerative therapies. Both biotechs highlight cutting-edge pipeline advancements amid sector volatility, offering insights into growth potential and risk. Traders seeking momentum plays and long-term investors focused on clinical catalysts will find value in analyzing their relative performance, market positioning, and recent developments in this dynamic environment.
BBIO Overview and Recent Performance
BridgeBio Pharma (BBIO) is a biopharmaceutical firm developing medicines for genetic diseases and oncology. Its portfolio includes approved products like Attruby for transthyretin-mediated amyloidosis (ATTR-CM, a type of cardiomyopathy) and NULIBRY for molybdenum cofactor deficiency, alongside late-stage candidates such as encaleret for hypoparathyroidism. In recent market activity, BBIO has shown robust upward momentum, trading near its 52-week high of around $85 from a low of $32, with shares reflecting strong one-year gains exceeding 100%. Positive sentiment stems from multiple Phase 3 trial successes, reinforcing its growth trajectory and attracting investor confidence despite biotech sector pressures.
PMN Overview and Recent Performance
ProMIS Neurosciences (PMN) focuses on antibody therapies for neurodegenerative diseases like Alzheimer's and ALS, leveraging its ProMIS platform combining protein biology, physics, and supercomputing. Lead candidate PMN310, a monoclonal antibody (mAb, lab-produced antibody mimicking immune response) targeting toxic oligomers, advances in Alzheimer's trials. Recent weeks have seen PMN exhibit volatility, with shares between $6 and $40 over 52 weeks and year-to-date appreciation near 60%. Trial milestones, including exceeding enrollment in the Phase 1b PRECISE-AD study and up to $175 million in financing, have supported sentiment, though high cash burn remains a factor.
Trending AI Robots
Tickeron's Trending AI Robots page showcases the platform's top-performing AI trading bots, selected from hundreds available that trade thousands of tickers across stocks, ETFs, and crypto. Out of 351 total bots, 25 elite ones earn a spot based on suitability for current market conditions, featuring diverse strategies like signal agents, virtual agents, and brokerage agents. These bots vary in timeframes (from 5-minute to 60-minute), analysis types (technical or fundamental), and volatility tolerance (low to high), with real-time signals enabling copy trading without minimum balances. Exploring these can reveal automated insights into stocks like BBIO and PMN; visit the page to discover top performers today.
Head-to-Head Comparison
BridgeBio Pharma (BBIO) and ProMIS Neurosciences (PMN) both target biotech innovation but diverge in scale and maturity. BBIO's commercial revenues from approved drugs contrast PMN's pre-revenue status, yielding a 140x market cap advantage for BBIO. Growth drivers include BBIO's late-stage catalysts versus PMN's early trials, with BBIO showing steadier recent momentum and lower relative volatility. Risk factors weigh heavier on PMN due to funding needs, while BBIO offers diversified exposure. Sector-wise, genetic therapies provide BBIO broader appeal amid neuro-specific sentiment for PMN.
Tickeron AI Verdict
Tickeron's AI currently leans toward BridgeBio Pharma (BBIO) over ProMIS Neurosciences (PMN), citing superior trend consistency, established revenue streams, and multiple late-stage catalysts positioning it favorably in recent market activity. While PMN holds upside from trial progress, BBIO's relative stability enhances probabilistic outperformance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBIO is a Buy and PMN is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BBIO’s FA Score shows that 1 FA rating(s) are green whilePMN’s FA Score has 0 green FA rating(s).
- BBIO’s FA Score: 1 green, 4 red.
- PMN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BBIO’s TA Score shows that 3 TA indicator(s) are bullish while PMN’s TA Score has 5 bullish TA indicator(s).
- BBIO’s TA Score: 3 bullish, 3 bearish.
- PMN’s TA Score: 5 bullish, 4 bearish.
Price Growth
BBIO (@Biotechnology) experienced а +1.32% price change this week, while PMN (@Biotechnology) price change was +6.22% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.11%. For the same industry, the average monthly price growth was +3.26%, and the average quarterly price growth was +1969.89%.
Reported Earning Dates
BBIO is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Biotechnology (+7.11% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BBIO | PMN | BBIO / PMN | |
| Capitalization | 13.5B | 95.7M | 14,107% |
| EBITDA | -535.2M | -40.9M | 1,308% |
| Gain YTD | -9.923 | 56.410 | -18% |
| P/E Ratio | N/A | 7.78 | - |
| Revenue | 580M | 0 | - |
| Total Cash | 940M | 63.8M | 1,473% |
| Total Debt | 2.49B | 4.05M | 61,531% |
BBIO | PMN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 85 | 100 | |
SMR RATING 1..100 | 100 | 99 | |
PRICE GROWTH RATING 1..100 | 51 | 62 | |
P/E GROWTH RATING 1..100 | 100 | 97 | |
SEASONALITY SCORE 1..100 | 12 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BBIO's Valuation (3) in the null industry is significantly better than the same rating for PMN (90). This means that BBIO’s stock grew significantly faster than PMN’s over the last 12 months.
BBIO's Profit vs Risk Rating (85) in the null industry is in the same range as PMN (100). This means that BBIO’s stock grew similarly to PMN’s over the last 12 months.
PMN's SMR Rating (99) in the null industry is in the same range as BBIO (100). This means that PMN’s stock grew similarly to BBIO’s over the last 12 months.
BBIO's Price Growth Rating (51) in the null industry is in the same range as PMN (62). This means that BBIO’s stock grew similarly to PMN’s over the last 12 months.
PMN's P/E Growth Rating (97) in the null industry is in the same range as BBIO (100). This means that PMN’s stock grew similarly to BBIO’s over the last 12 months.
| BBIO | PMN | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 73% |
| Advances ODDS (%) | 19 days ago 80% | 2 days ago 84% |
| Declines ODDS (%) | 22 days ago 80% | 9 days ago 90% |
| BollingerBands ODDS (%) | N/A | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 90% |
Advertisement
BBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with AXON. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To BBIO | 1D Price Change % | ||
|---|---|---|---|---|
| BBIO | 100% | +3.97% | ||
| AXON - BBIO | 44% Loosely correlated | -3.16% | ||
| ARRY - BBIO | 43% Loosely correlated | +6.75% | ||
| PMN - BBIO | 43% Loosely correlated | +1.28% | ||
| KURA - BBIO | 41% Loosely correlated | +4.33% | ||
| DYN - BBIO | 39% Loosely correlated | +5.51% | ||
More | ||||
PMN and
Correlation & Price change
A.I.dvisor indicates that over the last year, PMN has been loosely correlated with CNSP. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if PMN jumps, then CNSP could also see price increases.
| Ticker / NAME | Correlation To PMN | 1D Price Change % | ||
|---|---|---|---|---|
| PMN | 100% | +1.28% | ||
| CNSP - PMN | 51% Loosely correlated | -5.32% | ||
| SYRE - PMN | 44% Loosely correlated | +13.54% | ||
| BBIO - PMN | 42% Loosely correlated | +3.97% | ||
| ABOS - PMN | 33% Poorly correlated | +5.53% | ||
| CTNM - PMN | 28% Poorly correlated | -3.02% | ||
More | ||||